HARBIN, China, Dec. 9 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that its subsidiary, Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang"), successfully obtained production approval from the State Food and Drug Administration (SFDA) in China for two of its newly developed drugs.
Tinea Liniment is a traditional Chinese medicine intended for the treatment of athlete's foot (tinea pedis), hand ringworm (tinea manus), jock itch (tinea cruris) and fungal skin infection (tinea versicolor). These fungal infections are difficult to cure and new outbreaks occur frequently. Compared to existing products, Tinea Liniment has been shown to be more effective in treating these infections with lower recurrence, making it competitive in the market for these products.
Skincare Cream is a traditional Chinese medicine intended for the treatment of skin diseases such as acne, bottle nose, chromophytosis and vitiligo. There are currently few similar TCM products on the market.
"These new drugs address a number of relatively common diseases in China and we are excited to receive production approval from the SFDA," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Our marketing team is currently examining the market potential for these drugs, which we believe is very large, as we continue to pursue our strategy of winning market share by expanding our product mix."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact: Company Contact: Mr. Yu-Bo Hao, Board Secretary China Sky One Medical, Inc. Tel: +86-451-5399-4069 Email: firstname.lastname@example.org Investor Relations Contact: Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 Email: email@example.com Web: http://www.ccgirasia.com
|SOURCE China Sky One Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved